AM Rx vs Ro
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
AM Rx
Best for patients with insurance seeking brand-name GLP-1 access (review regulatory warnings carefully)Starting at $25/mo
Ro
Best for broadest GLP-1 formulary including Foundayo on day-one of launchStarting at $149/mo
Side-by-Side Comparison
| Feature | AM Rx | Ro |
|---|---|---|
| Overall Score | 5.9/10 | ✓7.9/10 |
| Starting Price | ✓$25/mo | $149/mo |
| Editorial Rating | 3 ★ /5 | ✓4 ★ /5 |
| Features | 6 features | ✓7 features |
| States Available | 0 | 0 |
| Compounded | ✓ Yes | — |
| Brand Name | ✓ Yes | ✓ Yes |
| FSA/HSA Accepted | — | — |
| FDA Warnings | 2 warnings | ✓None |
Pros & Cons
AM Rx
Pros
- ✓Insurance coordination for brand-name GLP-1s — as low as $25/mo
- ✓All four major brand-name GLP-1s available (Ozempic, Wegovy, Zepbound, Mounjaro)
- ✓HSA and FSA accepted
- ✓Video visits available (not just async) with providers averaging 10+ years experience
- ✓Compounded semaglutide from $151/mo quarterly
Cons
- ✗Active FTC/DOJ lawsuit for deceptive billing and subscription practices (ROSCA violations)
- ✗Two FDA warning letters (Sept 2025, Feb 2026) for misbranding compounded GLP-1 products
- ✗Novo Nordisk false advertising lawsuit (Aug 2025)
- ✗Parent entity Zealthy has BBB D- rating with 2,370+ complaints
- ✗Trustpilot 2.0/5 — 85% one-star reviews citing billing disputes and unreachable support
- ✗No visible LegitScript certification or PCAB accreditation
- ✗No named pharmacy partners — compounding source not disclosed
- ✗No FDA compounding disclaimer on the website
- ✗State availability not publicly disclosed
- ✗Founder Kyle Robertson previously ran Cerebral, which settled FTC charges for similar practices
- ✗Same corporate entity (FitRX LLC) as Zealthy and FitRx — shares regulatory history
Ro
Pros
- ✓Most comprehensive GLP-1 formulary in telehealth — compounded semaglutide, brand-name Wegovy, brand-name Zepbound, and the new oral Foundayo (orforglipron) all available on one platform
- ✓Among the first telehealth providers to launch Foundayo on day one of the Lilly partner rollout (April 9 2026)
- ✓Clinician-led plan selection — 'patients connect with a licensed provider and, if appropriate, determine which GLP-1 is the best option based on their insurance coverage, the cost, and their unique clinical needs and health goals'
- ✓Nationwide delivery network — Ro reports having served patients in 'nearly every single county in the United States, including 99% of primary care deserts'
- ✓Both cash-pay and insurance-eligible options under one roof
Cons
- ✗Foundayo on Ro requires a recurring membership in addition to the $149/mo cash drug price — total monthly cost is higher than the headline number
- ✗Specific Foundayo dose-tier pricing above the lowest dose not publicly disclosed in the launch announcement — needs intake to confirm
- ✗State availability and pharmacy partners not itemized publicly — requires signup intake to verify
- ✗Like all telehealth GLP-1 providers, Ro charges separately for the program (membership) and the medication; users sometimes confuse the bundled vs. unbundled pricing models
Our Verdict
Ro edges out AM Rx with a higher overall score of 7.9/10 and is particularly strong for broadest GLP-1 formulary including Foundayo on day-one of launch. AM Rx remains a solid alternative, especially if you're looking for patients with insurance seeking brand-name GLP-1 access (review regulatory warnings carefully).
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.